The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
 
Hun Ju Lee
Consulting or Advisory Role - Bristol-Myers Squibb; Guidepoint Global
Research Funding - Bristol-Myers Squibb; Celgene; Celgene; Oncternal Therapeutics; Seagen; Takeda
 
Michael Y. Choi
Consulting or Advisory Role - Abbvie/Genentech; Rigel
Research Funding - Pharmacyclics (Inst)
 
Tanya Siddiqi
Consulting or Advisory Role - AstraZeneca; BeiGene; Juno Therapeutics; Pharmacyclics
Speakers' Bureau - Pharmacyclics/Janssen; Seagen
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Juno Therapeutics
 
William G. Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Cyclacel; Emergent BioSolutions; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Loxo; miRagen; Oncternal Therapeutics, Inc; Pharmacyclics; Sunesis Pharmaceuticals; Xencor
 
Jacqueline Claudia Barrientos
Honoraria - Janssen
Consulting or Advisory Role - Abbvie; Bayer; Genentech; Gilead Sciences; Pharmacyclics; Sandoz
Research Funding - AstraZeneca (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst)
Travel, Accommodations, Expenses - Janssen
 
Nicole Lamanna
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Abbvie; Abbvie; Abbvie; Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BeiGene; BeiGene; BeiGene; BeiGene; BeiGene; BeiGene; BeiGene; BeiGene; Celgene; Celgene; Celgene; Celgene; Celgene; Celgene; Celgene; Celgene; Genentech; Genentech; Genentech; Genentech; Genentech; Genentech; Genentech; Genentech; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics
Research Funding - Abbvie; Abbvie; Abbvie; Abbvie; Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BeiGene; BeiGene; BeiGene; BeiGene; BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); Genentech; Genentech; Genentech; Genentech; Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Juno Therapeutics; Juno Therapeutics; Juno Therapeutics; Juno Therapeutics; Juno Therapeutics (Inst); Juno Therapeutics (Inst); Juno Therapeutics (Inst); Juno Therapeutics (Inst); MindSight Pharmaceuticals; MindSight Pharmaceuticals; MindSight Pharmaceuticals (Inst); MindSight Pharmaceuticals (Inst); MindSight Pharmaceuticals (Inst); MindSight Pharmaceuticals (Inst); Ming; Ming (Inst); Oncternal Therapeutics; Oncternal Therapeutics; Oncternal Therapeutics; Oncternal Therapeutics; Oncternal Therapeutics (Inst); Oncternal Therapeutics (Inst); Oncternal Therapeutics (Inst); Oncternal Therapeutics (Inst)
 
Alec Goldenberg
Patents, Royalties, Other Intellectual Property - Royalties for bone marrow biopsy needle IP
 
Iris Isufi
Consulting or Advisory Role - AstraZeneca; Celgene/Jazz; Kite, a Gilead company
Travel, Accommodations, Expenses - Celgene; Kite, a Gilead company
 
Joseph M. Tuscano
Honoraria - Amgen; Celgene; Seagen
Speakers' Bureau - Amgen; Celgene; Seagen
Research Funding - Celgene; Genentech; Novartis; Pharmacyclics; Seagen; Spectrum Pharmaceuticals
 
Suki Subbiah
No Relationships to Disclose
 
Elizabeth Kristine Weihe
Employment - Toragen (I)
Stock and Other Ownership Interests - Toragen (I)
Honoraria - AstraZeneca (I); Jounce Therapeutics (I)
Consulting or Advisory Role - AstraZeneca (I); Jounce Therapeutics (I)
Research Funding - Pfizer (I); Varian Medical Systems (I)
Patents, Royalties, Other Intellectual Property - Toragen (I)
 
Xen Ianopulos
Employment - Oncternal Therapeutics, Inc
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc
Travel, Accommodations, Expenses - Oncternal Therapeutics, Inc
 
James Bradley Breitmeyer
Employment - Oncternal Therapeutics, Inc
Leadership - Oncternal Therapeutics, Inc; Otonomy; Zogenix
Stock and Other Ownership Interests - Bavarian Nordic; Oncternal Therapeutics, Inc; Oncternal Therapeutics, Inc (I); Otonomy; Zogenix
Patents, Royalties, Other Intellectual Property - Inventor on patent(s)
Travel, Accommodations, Expenses - Oncternal Therapeutics, Inc; Zogenix
 
Frank J. Hsu
Employment - Immune Design; Oncternal Therapeutics
Leadership - Immune Design; Oncternal Therapeutics
Stock and Other Ownership Interests - Immune Design; Oncternal Therapeutics, Inc
Travel, Accommodations, Expenses - Immune Design; Oncternal Therapeutics
 
Michael Wang
Stock and Other Ownership Interests - More Health
Honoraria - AstraZeneca; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries; Onclive; oncology business review; Peerview; Pharmacyclics; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; AxImmune; Bioinvent; Celgene; Guidepoint Global; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; More Health; Noble Insights; Pharmacyclics/Janssen; Pulse Biosciences
Research Funding - Acerta Pharma; Amgen; AstraZeneca; BeiGene; Bioinvent; Celgene; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; Novartis; Oncternal Therapeutics; Pharmacyclics; VelosBio; Verastem
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries
 
Catriona HM Jamieson
Leadership - Impact Biomedicines
Research Funding - Celgene; Johnson & Johnson
 
Thomas J. Kipps
Employment - Moores Cancer Center
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc
Honoraria - Abbvie; Celgene; Dava Oncology; Genentech; Gilead Sciences; Janssen; Pharmacyclics; Roche
Consulting or Advisory Role - Abbvie; Celgene; Dava Oncology; Genentech; Gilead Sciences; Janssen; Pharmacyclics; Roche
Speakers' Bureau - Abbvie/Genentech; DAVA Pharmaceuticals; Gilead Sciences; Pharmacyclics/Janssen; Verastem/Pharmacyclics
Research Funding - Breast Cancer Research Foundation (Inst); California Institute for Regenerative Medicine (CIRM) (Inst); Celgene (Inst); Leukemia and Lymphoma Society (Inst); MD Anderson Cancer Center (Inst); National Cancer Institute (Inst); National Cancer Institute (Inst); NIH (Inst); Oncternal Therapeutics, Inc (Inst); Pharmacyclics/Janssen (Inst); Velos (Inst); Velos (Inst); Velos (Inst)
Patents, Royalties, Other Intellectual Property - Cirmtuzumab was developed by Thomas J. Kipps in the Thomas J. Kipps laboratory and licensed by the University of California to Oncternal Therapeutics, Inc., which provided stock options and research funding to the Thomas J. Kipps laboratory. (Inst)
Travel, Accommodations, Expenses - Abbvie/Pharmacyclics; Bionest Partner; Breast Cancer Research Foundation; Celgene; Dava Oncology; European Research Initiative on CLL (ERIC); Genentech/Roche; German CLL Study Group (GCLLSG); Gilead Sciences; Indy Hematology Review; International Workshop on Non-Hodgkin Lymphoma; Janssen; National Cancer Institute; NCCN; OncLive; Patient Power; Shenzhen Cancer Care Center; Society of Hematologic Oncology; TG Therapeutics; University of Nebraska Medical Center; Verastem